Tourmaline Bio, Inc. (“Tourmaline”) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines that establish new standards of care for patients with life-altering inflammatory and immune diseases, announces that it has entered into a merger agreement with Novartis AG (“Novartis”), pursuant to which Novartis will acquire Tourmaline for $48.00 per share in cash at closing, or a total equity value of approximately $1.4 billion. This represents a premium of 59% to Tourmaline’s closing stock price on September 8, 2025, the last trading day before the announcement of the transaction, and 127% to Tourmaline’s 60-day volume-weighted average stock price as of that same date.
Read the full article: Tourmaline Bio Enters into Agreement to Be Acquired by Novartis AG //
Source: https://www.globenewswire.com/news-release/2025/09/09/3146562/0/en/Tourmaline-Bio-Enters-into-Agreement-to-be-Acquired-by-Novartis-AG.html